STAT

APRIL 22, 2024

The Supreme Court decision to overturn Roe v. Wade has transformed not just abortion access but maternal health care across the United States, causing physicians in states with restrictive laws to shift treatment of conditions including ectopic pregnancy and miscarriage. The full scale of the impact, though, has been obscured in a polarized political climate where physicians are often afraid to speak out, or are blocked by their hospitals from talking about their experiences post-Dobbs.

Hospitals 355

Hospitals 355

PharmaVoice

APRIL 22, 2024

The fast-acting medication is one of a few new approaches being tested for the crippling condition.

321

321

STAT

APRIL 22, 2024

Last month, nearly 40,000 medical students were accepted into residency programs on “Match Day.” Surrounded by family and friends, these soon-to-be-physicians opened envelopes revealing where they would begin their careers. This moment marked the culmination of a residency match process that requires medical students to make a series of choices and rankings about which medical specialty to practice and at which health system, along with the various lifestyle factors inherent in suc

325

325

PharmaVoice

APRIL 22, 2024

Why the legislation could throw a wrench into the supply chain for advanced therapies and how the industry has responded.

130

130

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

STAT

APRIL 22, 2024

The ambitious idea of using CRISPR to cure genetic diseases before birth is one step closer to reality. Scientists reported on Monday that they used a form of the technology known as “ base editing ” to alter the DNA of laboratory monkeys in the womb, substantially reducing the levels of a toxic protein that causes a fatal liver disease before the animals had even been born.

Packaging 325

Packaging Hospitals 325

The Pharmacist

APRIL 22, 2024

Concerns have been raised over the level of exclusion and discrimination reportedly faced by pharmacists with a disability or long-term condition. The Pharmacists’ Defence Association (PDA) has revealed early findings of its disability discrimination survey, which is designed to gather the workplace experiences of members who have a long-term condition or disability.

111

111

BioPharma Dive

APRIL 22, 2024

The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

Diabetes 109

Diabetes 109

STAT

APRIL 22, 2024

In human biology, the protein dystrophin is a shining example of Joni Mitchell’s classic line, “you don’t know what you’ve got ’til it’s gone.” Dystrophin stabilizes muscle cells. In its absence, the house of cards comes down. For my 6-year-old son, Charlie, dystrophin will govern how long he lives. And how much dystrophin he has in his body depends on the ability of drug developers to continue improving it with innovation.

Drug Development 301

Drug Development 301

BioPharma Dive

APRIL 22, 2024

A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of the complex cellular treatments.

117

117

STAT

APRIL 22, 2024

WASHINGTON — Biden officials are still pressing to shore up abortion protections amid an onslaught of legal challenges, one of which is slated for Supreme Court arguments this week. The Department of Health and Human Services on Monday released a final rule that would put abortion services under the same federal privacy protections as other health care data covered by the Health Insurance Portability and Accountability Act, or HIPAA.

HIPAA 297

HIPAA 297

Advertisement

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

Pharmacy Management

pharmaphorum

APRIL 22, 2024

Pharmaceutical companies stand to gain significant benefits from technological innovation in the form of improved data analytics, streamlined healthcare processes, and enhanced patient outcomes. Explore the potential advantages for the pharma industry.

Pharmaceutical Companies 102

Pharmaceutical Companies Pharmaceutical Companies 102

STAT

APRIL 22, 2024

Makena, once the only available treatment to prevent preterm birth, has had its share of controversy. A yearslong debate over the drug’s effectiveness led the Food and Drug Administration to withdraw its approval of the product and demand it be pulled from the market after a confirmatory trial couldn’t replicate the results of a key study.

295

295

Pharmaceutical Technology

APRIL 22, 2024

Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.

Chemotherapy 103

Chemotherapy 103

STAT

APRIL 22, 2024

You’re reading the web version of Health Care Inc.,  STAT’s weekly newsletter following the flow of money in medicine.  Sign up to get it in your inbox every Monday.  Embracing Wall Street, stiff-arming Congress (for now) We finally got an answer of how much financial damage the Change  Healthcare  cyberattack did to UnitedHealth Group: Basically none.

Hospitals 264

Hospitals 264

The Pharmacist

APRIL 22, 2024

March saw the highest number of measles cases yet this year as the outbreak continues to spread around the country. The latest figures from the UK Health Security Agency showed there were 299 laboratory confirmed cases of measles in March. This is higher than the 274 cases seen in January when officials declared a national incident […] The post March sees highest number of measles cases yet as outbreak continues to spread appeared first on The Pharmacist.

Vaccines 100

Vaccines 100

STAT

APRIL 22, 2024

The federal government is for the first time requiring nursing homes to have minimum staffing levels after the Covid-19 pandemic exposed grim realities in poorly staffed facilities  for older and disabled Americans. Vice President Kamala Harris announced the final rules on Monday before a trip to La Crosse, Wis., where she will talk to nursing home care employees about their work.

Nursing Homes 264

Nursing Homes 264

BioPharma Dive

APRIL 22, 2024

A collaboration with BioArctic will focus on a technology designed to more effectively deliver drugs in the brain, following similar efforts by Roche.

110

110

STAT

APRIL 22, 2024

Good morning, everyone, and welcome to another working week. We hope the weekend respite was invigorating and inspiring, because that oh-too predictable routine of online meetings, phone calls, and deadlines has returned. But what can you do? The world, such as it is, continues to spin. So to give it a nudge in a better direction, we are firing up the coffee kettle to brew some cups of stimulation.

Specialty Pharmacies 206

Specialty Pharmacies 206

Pharmaceutical Technology

APRIL 22, 2024

Discover how Avidity Biosciences' patented polynucleic acid molecule conjugate targets the DUX4 gene to combat FSHD. Learn more about this groundbreaking approach in gene therapy.

98

98

STAT

APRIL 22, 2024

Want to stay on top of the science and politics driving biotech today?  Sign up  to get our biotech newsletter in your inbox. Morning! Hope you had a delightful weekend. Up today: an exclusive look at the scientific mix-up behind the approval of preterm birth drug Makena. We hear from a mother of a son with Duchenne muscular dystrophy who wants to ensure the FDA’s accelerated approval pathway stays strong, and more.

196

196

Outsourcing Pharma

APRIL 22, 2024

Ahead of CPHI North America, we caught up with Lisa Stiles, director, business development at Selkirk Pharma, an exhibitor at the event, to find out how the CMO is navigating regulatory changes, challenges and more.

98

98

pharmaphorum

APRIL 22, 2024

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials. TGCT is a rare disease affecting the joints and tendons caused by overproduction of the protein CSF-1, which stimulates the proliferation of various cell types, inflammation, and destruction of the matrix of the joint.

96

96

Outsourcing Pharma

APRIL 22, 2024

In a significant development for the multiple myeloma community, Menarini Stemline UK today welcomed the final draft guidance from the National Institute for Health and Care Excellence (NICE).

98

98

The Pharmacist

APRIL 22, 2024

The Department of Health and Social Care (DHSC) is looking to address ‘any loopholes’ in prescribing practices following a major review into gender identity services for children and young people, the pharmacy minister has said. This includes working with the General Pharmaceutical Council (GPhC) to ‘define the dispensing responsibilities’ of pharmacists providing private prescriptions, Dame […] The post DHSC to address ‘any loopholes’ in prescribing practices following Cass Review appeare

Online Pharmacies 96

Online Pharmacies 96

Outsourcing Pharma

APRIL 22, 2024

Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S. market.

98

98

Pharmaceutical Technology

APRIL 22, 2024

Discover how BioMarin Pharmaceutical's patent for PAL variants offers a groundbreaking method to treat PKU in adolescents. Administering AvPAL variants weekly over 50 weeks effectively reduces blood phenylalanine levels.

96

96

Outsourcing Pharma

APRIL 22, 2024

After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers.

98

98

Express Pharma

APRIL 22, 2024

Zydus Lifesciences has launched Mirabegron Extended-Release Tablets, 25 mg in the US market. The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq Extended-Release Tablets). Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market and is prepared to launch Mirabegron Extended-Release Ta

94

94

European Pharmaceutical Review

APRIL 22, 2024

The USP Microbiology Expert Committee is due to vote on the proposed Chapter <86> to approve bacterial endotoxin testing using non-animal derived reagents between 21 June and 1 July 2024. Jaap Venema , Chief Science Officer, USP shared with EPR that the chapter is helping to guide manufacturers how to the adopt these methods and provides “a path to wider adoption”.

92

92

Express Pharma

APRIL 22, 2024

Despite the ongoing uncertainties surrounding macroeconomic activities, fluctuating interest rates, and changes in the Medicare Drug Price Negotiation landscape, the top 20 global biopharma companies experienced a promising first quarter this year. They reported a total increase of 9.6 per cent in market capitalisation from $3.67 trillion as on 31 December 2023 to $4 trillion as on 31 March 2024, reveals GlobalData.

Drug Pricing 93

Drug Pricing Diabetes Vaccines 93

Outsourcing Pharma

APRIL 22, 2024

Kynos Therapeutics Ltd, based in Edinburgh, UK, focuses on developing small molecule kynurenine 3-monooxygenase (KMO) inhibitors for inflammatory disorders.

98

98

pharmaphorum

APRIL 22, 2024

Bristol-Myers Squibb has shored up manufacturing of its CAR-T therapies by reserving exclusive capacity wt contract manufacturer Cellares in $380m deal

90

90

Outsourcing Pharma

APRIL 22, 2024

Pacylex Pharmaceuticals Inc. has announced the presentation of phase 1 safety and efficacy findings for small molecule drug zelenirstat for cancer treatment.

97

97

Pharmaceutical Technology

APRIL 22, 2024

GS-6212 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS).

98

98

Pharma Times

APRIL 22, 2024

The neurodegenerative condition currently affects more than 944,000 people living in the UK

110

110